TAK-653 Research Guide: AMPA-Receptor Potentiation

What Is TAK-653?

TAK-653 is a synthetic small molecule — not a peptide — whose generic (INN) name is osavampator. The same compound carries two development codes from its corporate history: TAK-653 (originated at Takeda) and NBI-1065845 (Neurocrine Biosciences, which licensed it worldwide outside Japan). It is classed as a selective AMPA-receptor positive allosteric modulator (AMPA-R PAM) — an "AMPAkine"-type molecule, but more selective than the classic compounds in that lineage.

A frequent point of confusion is worth flagging up front: the correct Neurocrine designation is NBI-1065845, confirmed in the company's own materials ("osavampator, formerly NBI-1065845/TAK-653"). The similar-looking code NBI-1065846 refers to a different, unrelated Neurocrine compound; any source applying "-1065846" to TAK-653 is in error.

Mechanism of Action: What the Research Shows

TAK-653 is a positive allosteric modulator of the AMPA subtype of ionotropic glutamate receptors. It binds an allosteric site on the receptor and potentiates AMPA-receptor-mediated currents in response to glutamate — slowing receptor deactivation and desensitization — thereby enhancing fast excitatory glutamatergic synaptic transmission. The published preclinical work describes it as highly selective for AMPA over the kainate and NMDA receptor subtypes.

The Defining Feature: Minimal Agonism

The property the literature returns to most often is minimal intrinsic agonism. TAK-653 potentiates the receptor's response to the brain's own endogenous glutamate rather than directly opening the channel on its own. This "amplify, don't activate" behavior is proposed to underlie a wide margin between its procognitive/antidepressant-like activity and seizure liability — a meaningful distinction for a receptor class where over-activation carries a theoretical excitotoxicity and seizure risk.

Downstream Signaling

Preclinical work links AMPA potentiation to BDNF release and activation of Akt/ERK→mTOR/p70S6K signaling in cortical neurons — a synaptic-plasticity pathway that conceptually overlaps the proposed mechanism of ketamine's rapid antidepressant-like effect. The notable difference is route: TAK-653 reaches that pathway through direct AMPA potentiation, without NMDA antagonism and without the dissociative/psychotomimetic signaling associated with ketamine. That mechanistic contrast is discussed further in the comparison section below.

What the Research Literature Reports

TAK-653 sits unusually high on the evidence ladder for a compound sold in the research-use space — this is a genuine clinical-stage pharmaceutical, not a preclinical-only orphan. The findings below describe what the published literature has observed in its original study populations; none of it is presented as a use indication for, or a claim about, research-grade material.

Preclinical Pharmacology

Hara et al., Pharmacology Biochemistry and Behavior, 2021 (vol. 211, 173289; PMID 34655652) characterized TAK-653 as an AMPA-R potentiator with minimal agonistic activity. The study reported antidepressant-like effects in a rat reduction-of-submissive-behavior model under sub-chronic dosing, activation of Akt/ERK→mTOR/p70S6K signaling in cortical neurons, and a favorable safety/seizure margin. Notably, and unlike ketamine, it produced no hyperlocomotor (psychotomimetic-index) response in that work.

Human Target Engagement (TMS Biomarker)

O'Donnell, Dijkstra, Damar et al., Translational Psychiatry, 2021 (11:325; PMID 34045439) reported that a 6 mg dose of TAK-653 — but not 0.5 mg — significantly increased TMS motor-evoked potential (MEP) amplitude roughly 2.5 hours post-dose in healthy humans, paralleling an increase in TMS-evoked responses in rats at matched plasma exposures. The authors describe this as the first demonstration of a circuit-level biomarker sensitive to direct AMPA-receptor positive modulation. An open-label ketamine arm was included only to gauge assay sensitivity and was not formally compared, given conflicting prior ketamine–TMS literature. (Registered as NCT03792672.)

Human CNS Pharmacology & Safety

Dijkstra, O'Donnell, Klaassen et al., Translational Psychiatry, 2022 (12:408; PMID 36153330) ran a randomized, double-blind, placebo-controlled three-way crossover in 24 healthy volunteers (placebo, 0.5 mg, 6 mg). TAK-653 produced mild stimulant-like neurophysiological effects (increased saccadic peak velocity at both doses; improved smooth pursuit and adaptive tracking at 6 mg), with no effect on body sway or subjective drug effects, and — in contrast to ketamine — no dissociative effects, euphoria, or seizures. Pharmacokinetics: peak plasma (C_max) around 2.5 h, a long terminal half-life of roughly 33–48 h, and CSF levels indicating rapid brain penetration.

Phase 2 (Company-Reported)

The Phase 2 "SAVITRI" trial evaluated adjunctive osavampator (NBI-1065845/TAK-653) in major depressive disorder with inadequate antidepressant response: 183 adults randomized roughly 2:1:1 to placebo, 1 mg, or 3 mg once-daily over 8 weeks. As reported by Neurocrine, the 1 mg arm met its primary and key secondary endpoints with significant MADRS reductions at Day 28 and Day 56, and a Phase 3 registrational program was initiated in January 2025.

Handling & Reconstitution for Research

A published, compound-specific reconstitution and storage protocol for TAK-653 could not be verified from a primary source, so the notes below are generic small-molecule laboratory practice, not a validated TAK-653 method. Confirm every figure against your supplier's certificate of analysis.

Because TAK-653 is a non-peptide organic small molecule (C₁₉H₂₃N₃O₃S), it does not require the cold-chain and anti-aggregation precautions that peptides do. General handling considerations for a crystalline/lyophilized small-molecule powder of this type:

• Store desiccated and protected from light. Long-term storage for such powders is commonly at −20 °C, though vendor catalog pages vary — defer to the specific COA.
• Vehicle. For in-vitro use, scaffolds of this kind are typically dissolved in DMSO rather than water, since aqueous solubility tends to be low. The exact mg/mL and vehicle must come from the supplier's solubility data, which was not independently verified here.
• Equilibrate before opening. Bring powder to room temperature in a sealed container before opening to avoid condensation, and weigh in a low-humidity environment.
• Prepare what you'll use. For a 60 mg jar, prepare stock solutions only in volumes a study will consume, and record lot and COA against each preparation.

No human-use, dosing, or administration guidance is provided here. The doses cited in the published trials are study-specific clinical-investigation parameters and are not transferable to research-use material.

TAK-653 vs Ketamine & Classic Ampakines

Researchers typically search TAK-653 against three reference points. Keeping the distinctions straight matters, because the marketing shorthand around this compound is loose.

vs Ketamine / Esketamine

This is the rapid-acting comparator most often invoked. The shared idea is downstream AMPA-receptor activation and BDNF/mTOR-driven synaptic plasticity. The mechanistic divergence is the key point: TAK-653 reaches that downstream biology through direct AMPA potentiation, without NMDA antagonism and — per the human Phase 1 studies — without dissociation or euphoria. Any "as effective as ketamine" claim is not a validated head-to-head result; the one human study that included a ketamine arm used it only for assay calibration.

vs Classic Ampakines & Older AMPA PAMs

TAK-653 belongs to a lineage that includes earlier AMPA modulators such as CX-516, farampator (CX-691/Org 24448), tulrampator (S 47445), BIIB104 (PF-04958242), and mibampator (LY451646). Relative to those, TAK-653 is positioned as more selective, with minimal agonism and a wider reported seizure margin — the practical reason it advanced into clinical development where several predecessors stalled.

A Note on Nootropic / "AMPAkine" Queries

TAK-653 surfaces in consumer cognitive-enhancement searches alongside racetams and other "AMPAkines." That association is mechanistically adjacent at best and is not supported by the clinical literature for general cognitive-enhancement use — the human data establish target engagement and tolerability, not a validated nootropic effect.

Its Own Aliases

Finally, much of the apparent disagreement online is just naming: osavampator, TAK-653, and NBI-1065845 are one molecule. The easily-confused NBI-1065846 is a separate compound entirely.

Evaluating Research-Grade TAK-653 Supply

For reproducible work, the analytical documentation behind a vial matters as much as the molecule. Because TAK-653 is a small molecule rather than a peptide, the relevant identity checks differ slightly from peptide work, but the principle is the same.

1. A Batch-Specific Third-Party COA

A legitimate supplier provides a Certificate of Analysis for each lot, ideally generated by an independent lab. For a small molecule like this, the COA should report:

• HPLC purity — research-grade material should test high (≥98%, ideally ≥99%), with the chromatogram showing a clean single peak.
• Mass-spec confirmation — verifying the measured mass matches the expected ~373.5 g/mol for C₁₉H₂₃N₃O₃S, which is how you confirm you received the intended molecule and not a mislabeled or substituted compound.
• Batch / lot number and a recent test date linking the COA to your specific jar.

Elytra Labs publishes batch-specific third-party COAs for the research compounds we ship. Browse our current COA library → and see our guide to reading a COA for how to interpret the chromatogram and mass-spec data.

2. Honest Identity & Storage Documentation

Given the naming ambiguity around this compound, a supplier that correctly lists osavampator / NBI-1065845 (and not the mistaken "-1065846") and documents storage and solubility conditions is demonstrating real quality control. Verify the formula, molecular weight, and any handling figures against the lot-specific COA rather than trusting catalog copy.

Frequently Asked Research Questions

What is TAK-653 and what does it do?

TAK-653 (generic name osavampator; development codes TAK-653 and NBI-1065845; CAS 1358751-06-0) is a small-molecule selective AMPA-receptor positive allosteric modulator. It amplifies the receptor's response to the brain's own glutamate rather than acting as a stimulant or an NMDA blocker. It is investigational and not approved by any regulator.

What does "minimal agonism" mean for TAK-653?

It means the molecule potentiates the AMPA receptor rather than directly activating it — it requires endogenous glutamate to be present to have an effect. Preclinical work links this property to a wide reported margin between activity and seizure risk, which is a defining characteristic of the compound within its class.

Is TAK-653 the same as ketamine, and is it "as effective"?

No. They are mechanistically distinct: ketamine is an NMDA antagonist, while TAK-653 is a direct AMPA-receptor potentiator. The two converge on overlapping downstream plasticity signaling, but the published TMS study did not run a validated head-to-head comparison, so any "as effective as ketamine" claim is not supported by the data. Unlike ketamine, TAK-653 did not produce dissociation or euphoria in the Phase 1 studies.

What are TAK-653's pharmacokinetics in the human studies?

In the Phase 1 work, oral TAK-653 reached peak plasma around 2.5 hours, showed a long terminal half-life of roughly 33–48 hours, and produced CSF levels indicating rapid brain penetration (Dijkstra et al., 2022; PMID 36153330).

Is TAK-653 a peptide, and how should it be stored?

No — it is a non-peptide organic small molecule (C₁₉H₂₃N₃O₃S), so it does not need peptide-style cold-chain anti-aggregation handling. Generic practice for such powders is to keep them desiccated and light-protected (commonly −20 °C), dissolving in DMSO for in-vitro use. A compound-specific protocol could not be verified from a primary source, so confirm all storage and solubility figures against the lot's COA.